ReviewAnnals of medicine and surgery (2012)2025
When leukemia harms the kidneys: a scoping review of lysozyme-induced nephropathy in chronic myeloid leukemia and chronic myelomonocytic leukemia.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lysozyme-induced nephropathy (LyN) is a rare and underdiagnosed renal complication associated with hematologic malignancies, particularly chronic myelomonocytic leukemia (CMML), and less commonly, chronic myeloid leukemia (CML). This scoping review aims to consolidate current knowledge of the pathophysiology, diagnosis, clinical features, management, and epidemiology of LyN in these patient populations. Methods: In accordance with PRISMA-ScR guidelines, a comprehensive literature search was conducted through PubMed, Embase, and Scopus from inception to March 2025. Eligible studies included adult patients diagnosed with LyN in the setting of CMML or CML, confirmed either clinically or by renal biopsy. Extracted data included study design, lysozyme levels, hematologic and renal presentations, diagnostic modalities, treatment strategies, and outcomes. Results: A total of ten studies met the inclusion criteria: five case reports, three retrospective cohort studies, and two pathology-based reviews. The majority involved CMML patients with markedly elevated serum or urinary lysozyme levels. Renal biopsies consistently demonstrated proximal tubular injury, eosinophilic cytoplasmic granules, and positive lysozyme immunostaining, with occasional leukemic infiltration. Treatment focused on the underlying hematologic malignancy, using agents such as hypomethylating agents, hydroxyurea, or tyrosine kinase inhibitors. Renal outcomes varied, with four patients progressing to end-stage kidney disease and three requiring dialysis. Conclusion: Lysozyme-induced nephropathy is a clinically significant but frequently overlooked tubulointerstitial complication in patients with CMML and CML. Early recognition facilitated by lysozyme quantification and kidney biopsy may allow for timely therapeutic intervention and improved renal outcomes. Increased clinical awareness and further prospective studies are warranted to guide screening strategies and optimize management protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.